We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
SP, CGRP changes in pyridoxine induced neuropathic dogs with nerve growth factor gene therapy.
- Authors
Joo-Yeon Kang; Dae Young Yoo; Kwon-Young Lee; Wooseok Im; Manho Kim; Jung Hoon Choi; Hwa-Young Youn; Sae Hoon Kim; In Koo Hwang; Jin-Young Chung; Kang, Joo-Yeon; Yoo, Dae Young; Lee, Kwon-Young; Im, Wooseok; Kim, Manho; Choi, Jung Hoon; Youn, Hwa-Young; Kim, Sae Hoon; Hwang, In Koo; Chung, Jin-Young
- Abstract
<bold>Background: </bold>Nerve growth factor (NGF) is known not only as a major factor for neuronal plasticity but also as a pain stimulator. Although there have been several trials with NGF for its application in the regeneration or protection of the nervous system, the pain induced by NGF remains a challenge to be overcome. In this study, the pain induced by NGF gene therapy was evaluated.<bold>Results: </bold>Vehicle or recombinant dog NGF plasmid was administered into the intrathecal space of dogs. Twenty-four hours after the vehicle or NGF plasmid inoculation, dogs were subcutaneously treated with 150 mg/kg pyridoxine every day for 7 days. For pain assessment, physical examination and electrophysiological recording were performed. Only in the vehicle-treated group, weight loss occurred, while NGF plasmid inoculation significantly improved this physical abnormalities. In the vehicle-treated group, electrophysiological recordings showed that H-reflex disappeared at 24 h after the last pyridoxine treatment. However, in the NGF plasmid inoculated group, the H-reflex were normal. In the results of immunohistochemistry, the NGF plasmid administration efficiently expressed in the dorsal root ganglia and significantly increased the pyridoxine-induced reduction of calcitonin gene-related peptide (CGRP) immunoreactive neurons, but not in substance P immunoreactive neurons, in the dorsal root ganglia.<bold>Conclusions: </bold>Given these results, we reason that NGF gene therapy in pyridoxine induced neuropathic dogs does not induce neuropathic pain with this dosage, even with increasing the expression of CGRP.
- Subjects
VITAMIN B6; NERVE growth factor; GENE therapy; CALCITONIN gene-related peptide; NEUROPATHY; PLASMIDS; ELECTROPHYSIOLOGY; IMMUNOHISTOCHEMISTRY; DRUG metabolism; ANIMAL experimentation; DOGS; SENSORY ganglia; HYPERALGESIA; NERVE tissue proteins; NEURALGIA; NEURONS; NEUROPEPTIDES; NEUROTRANSMITTERS; PAIN measurement; RECOMBINANT proteins; H-reflex; THERAPEUTICS
- Publication
BMC Neuroscience, 2016, Vol 17, p1
- ISSN
1471-2202
- Publication type
journal article
- DOI
10.1186/s12868-015-0236-5